Compare Stocks: ELTX, PRQR, ORMP, and CHRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHRS Coherus Oncology	$1.26 -3.1%	$1.36	$1.09 ▼ $2.62	$200.85M	0.94	1.14 million shs	1.62 million shs
ELTX Elicio Therapeutics	$1.87	$2.73	$1.71 ▼ $16.00	$49.15M	1.29	373,636 shs	195,352 shs
ORMP Oramed Pharmaceuticals	$4.72 -0.6%	$4.56	$2.09 ▼ $5.47	$197.59M	1.19	207,837 shs	134,796 shs
PRQR ProQR Therapeutics	$1.70 -10.5%	$1.95	$1.33 ▼ $3.10	$200.19M	0.06	591,051 shs	1.13 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHRS Coherus Oncology	-3.08%	+3.28%	-7.35%	-14.86%	-19.23%
ELTX Elicio Therapeutics	0.00%	+5.65%	-37.25%	-50.13%	-83.21%
ORMP Oramed Pharmaceuticals	-0.63%	+2.16%	-2.07%	-5.60%	+89.56%
PRQR ProQR Therapeutics	-10.53%	-8.60%	-30.04%	+8.63%	-21.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHRS Coherus Oncology	$1.26 -3.1%	$1.36	$1.09 ▼ $2.62	$200.85M	0.94	1.14 million shs	1.62 million shs
ELTX Elicio Therapeutics	$1.87	$2.73	$1.71 ▼ $16.00	$49.15M	1.29	373,636 shs	195,352 shs
ORMP Oramed Pharmaceuticals	$4.72 -0.6%	$4.56	$2.09 ▼ $5.47	$197.59M	1.19	207,837 shs	134,796 shs
PRQR ProQR Therapeutics	$1.70 -10.5%	$1.95	$1.33 ▼ $3.10	$200.19M	0.06	591,051 shs	1.13 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHRS Coherus Oncology	-3.08%	+3.28%	-7.35%	-14.86%	-19.23%
ELTX Elicio Therapeutics	0.00%	+5.65%	-37.25%	-50.13%	-83.21%
ORMP Oramed Pharmaceuticals	-0.63%	+2.16%	-2.07%	-5.60%	+89.56%
PRQR ProQR Therapeutics	-10.53%	-8.60%	-30.04%	+8.63%	-21.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHRS Coherus Oncology	2.33	Hold	$11.00	773.02% Upside
ELTX Elicio Therapeutics	2.50	Moderate Buy	$19.75	956.15% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
PRQR ProQR Therapeutics	2.63	Moderate Buy	$7.50	341.18% Upside

Current Analyst Ratings Breakdown

Latest ELTX, PRQR, ORMP, and CHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Sell (D-)
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/20/2026	PRQR ProQR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/18/2026	ELTX Elicio Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	PRQR ProQR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	PRQR ProQR Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $3.00
6/26/2026	PRQR ProQR Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$11.00 ➝ $10.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHRS Coherus Oncology	$42.17M	4.62	N/A	N/A	$0.50 per share	2.52
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	$0.09 per share	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	$0.09 per share	52.36	$5.02 per share	N/A
PRQR ProQR Therapeutics	$18.36M	9.75	N/A	N/A	$0.53 per share	3.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHRS Coherus Oncology	$168.02M	-$1.03	N/A	N/A	N/A	-259.41%	-222.75%	-52.11%	11/5/2026 (Estimated)
ELTX Elicio Therapeutics	-$39.57M	-$2.17	N/A	N/A	N/A	N/A	-1,266.43%	-139.94%	11/12/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	1.15	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)
PRQR ProQR Therapeutics	-$47.73M	-$0.46	N/A	N/A	N/A	-223.51%	-73.83%	-35.14%	11/5/2026 (Estimated)

Latest ELTX, PRQR, ORMP, and CHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ELTX Elicio Therapeutics	-$0.5375	-$0.43	+$0.1075	-$0.43	N/A	N/A
8/13/2026	Q2 2026	PRQR ProQR Therapeutics	-$0.1303	-$0.0914	+$0.0389	-$0.09	$4.56 million	$10.00 million
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.25	-$0.19	+$0.06	-$0.13	$14.41 million	$14.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	5.30%	N/A	6.07%	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHRS Coherus Oncology	0.61	1.77	1.70
ELTX Elicio Therapeutics	1.20	2.77	2.77
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98
PRQR ProQR Therapeutics	N/A	3.49	3.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHRS Coherus Oncology	72.82%
ELTX Elicio Therapeutics	35.03%
ORMP Oramed Pharmaceuticals	12.73%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
CHRS Coherus Oncology	7.22%
ELTX Elicio Therapeutics	50.90%
ORMP Oramed Pharmaceuticals	20.77%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHRS Coherus Oncology	144	154.50 million	143.35 million	Optionable
ELTX Elicio Therapeutics	N/A	26.28 million	12.90 million	Not Optionable
ORMP Oramed Pharmaceuticals	13	41.60 million	32.96 million	Optionable
PRQR ProQR Therapeutics	166	105.36 million	96.51 million	Optionable

ELTX, PRQR, ORMP, and CHRS Headlines

Recent News About These Companies

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

September 23 at 8:00 AM | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts

September 23 at 2:14 AM | americanbankingnews.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages

September 23 at 2:13 AM | marketbeat.com

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

September 10, 2026 | finance.yahoo.com

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

September 9, 2026 | globenewswire.com

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Should You Sell?

September 9, 2026 | marketbeat.com

ProQR to Participate in Upcoming Investor Conferences in September 2026

September 2, 2026 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving Average - What's Next?

August 28, 2026 | marketbeat.com

ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts

August 21, 2026 | seekingalpha.com

ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results

August 15, 2026 | theglobeandmail.com

ProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validation

August 15, 2026 | theglobeandmail.com

ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones

August 13, 2026 | quiverquant.comQ

ProQR Announces Second Quarter 2026 Operating and Financial Results

August 13, 2026 | globenewswire.com

Bart Filius Purchases 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) Stock

July 29, 2026 | insidertrades.com

Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)

July 11, 2026 | theglobeandmail.com

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

July 4, 2026 | seekingalpha.com

ProQR Therapeutics (NASDAQ:PRQR) Director Purchases 150,000 Shares of Stock

July 1, 2026 | insidertrades.com

ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly

June 25, 2026 | msn.com

ProQR posts early-stage trial data for liver disease candidate

June 25, 2026 | msn.com

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

June 25, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX, PRQR, ORMP, and CHRS Company Descriptions

Coherus Oncology NASDAQ:CHRS

$1.26 -0.04 (-3.08%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.25 -0.01 (-0.40%)

As of 05:27 AM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Elicio Therapeutics NASDAQ:ELTX

$1.87 0.00 (0.00%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.00 (+0.27%)

As of 04:02 AM Eastern

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.72 -0.03 (-0.63%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.72 0.00 (0.00%)

As of 09/23/2026 04:15 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

ProQR Therapeutics NASDAQ:PRQR

$1.70 -0.20 (-10.53%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.73 +0.03 (+1.71%)

As of 09/23/2026 07:30 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELTX, PRQR, ORMP, and CHRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELTX, PRQR, ORMP, and CHRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELTX, PRQR, ORMP, and CHRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX, PRQR, ORMP, and CHRS Company Descriptions

Coherus Oncology NASDAQ:CHRS

Elicio Therapeutics NASDAQ:ELTX

Oramed Pharmaceuticals NASDAQ:ORMP

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELTX, PRQR, ORMP, and CHRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELTX, PRQR, ORMP, and CHRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELTX, PRQR, ORMP, and CHRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX, PRQR, ORMP, and CHRS Company Descriptions

Coherus Oncology NASDAQ:CHRS

Elicio Therapeutics NASDAQ:ELTX

Oramed Pharmaceuticals NASDAQ:ORMP

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools